This new plan has been developed to build on successes made and lessons learnt from implementation of the two initial plans and to provide a short to medium term strategic anchor against which preparedness and response plans to the corona virus disease COVID-19 epidemic in the country should focus o...n for the period June 2021 to June 2022.
more
Interium guidance, 25 June 2021Timely and accurate diagnostic testing is an essential tool in preventing and controlling the spread of COVID-19. This document describes recommendations for national testing strategies and the use of PCR and rapid antigen tests in different transmission scenarios of t...he COVID-19 outbreak, including how testing might be rationalized in low resource settings. All testing should be followed by a strong public health response including isolating those who test positive and providing them care, contact tracing and quarantine of contacts.
more
8 February 2021
This document highlights 10 well established Risk Communication and Community Engagement (RCCE) principles that have proven their power. Together they put communities at the heart of the roll out of new vaccines, treatments and tests and promote trust, the critical ingredient for al...l community action. Informed, engaged and empowered communities are the bedrock for the arrival of new vaccines, treatments and tests that will be introduced to reduce the spread of COVID-19 and save lives. With communities fully engaged and actively participating through the full cycle of planning, delivery and assessment for biomedical tools, demand for these tools can be increased, leading to widespread and effective uptake and use
more
This guide is intended to support national governments developing their national deployment and vaccination plans (NDVPs) for COVID-19 vaccines by outlining the roles, needs and opportunities for community health workers (CHWs) to contribute. This note builds on and is structured to align with the G...uidance on developing a national deployment and vaccination plan for COVID-19 vaccines. By providing CHW-relevant considerations for the VIRAT Tool, this document aims to support national governments in developing robust NDVPs for introducing COVID-19 vaccine(s) that leverage all the community-based deployment, implementation and monitoring tools at their disposal.
more
Preliminary overview of refugees and migrants self-reported impact of COVID-19
The study surveyed over 30,000 refugees and migrants living in 170 countries. Many of the respondents had fled war or dire economic conditions in their home country only to be faced with the additional challenges posed b...y COVID-19. Travel restrictions including border closures, suspension of resettlement travel, and last-minute deportation left many stranded or forced to stay in cramped, makeshift shelters or detention centers. Amid these uncertain, precarious conditions, many migrants described either a lack of access to health services or a fear of seeking them out — even if they were experiencing COVID-19 symptoms.
more
1 February 2021 to 31 January 2022
Обновленная версия. В этой версии приведены обновленные рекомендации относительно стратегии диагностического тестирования в контексте обновлённой классификаци...и способов передачи, мер общественного здравоохранения и социальных мер, эпиднадзора за общественным здравоохранением и установленных ВОЗ определений случая COVID-19. В данном руководстве учтено использование новых инструментов, таких, как диагностические экспресс-тесты для выявления антигенов (ДЭТ-АГ) и аспекты тестирования привитых лиц, а также тестирования на генетические мутации, связанные с вариантами. Кроме того, для этой версии разработаны приложения, включая подборку полезных ресурсов и десять компонентов расширения тестирования на субнациональном уровне.
more
Временные рекомендации27 мая 2021 г.
В этом документе изложена стратегия
Европейского региона ВОЗ в области
реагирования на COVID-19 и ликвидации
его последствий на основе актуальной
глобальной страт...гии ВОЗ в сфере борьбы
с COVID-19 на период с февраля по декабрь 2020 г.
more
7 June 2020 Version 1
Women in Myanmar have traditionally been underrepresented in public decision-making processes, a trend which is continuing in structures established to respond to COVID-19. This means that even as women are disproportionately affected by the crisis, they have less say in how t...heir communities and country respond to it, increasing the risk of a COVID-19 response that does not adequately address the needs and priorities of the most vulnerable women and girls.
more
An interagency guidance note on working with communities in high density settings to plan local approaches to preventing and managing COVID-19. This guidance note is intended for anyone involved in COVID-19 risk communication and community engagement (RCCE) efforts in complex and fragile settings in... Africa.
more
This document accompanies the interim guidance on “Strengthening Preparedness for COVID-19 in cities and urban settings”. It provides local authorities, leaders and policy-makers in cities with a checklist tool to ensure that key areas have been covered. An excel version that local authorities m...ay wish to adapt to meet their needs is also available. It allows filtering by steps of action; suggested domains and responsible teams within local governments for each action; and phase(s) of the emergency management cycle.
more
Nota científica
24 de abril de 2020
El desarrollo de inmunidad a un patógeno por infección natural es un proceso de varias etapas que suele producirse a lo largo de una o dos semanas. El organismo responde a una infección vírica de forma inmediata a través de una respuesta innata no específ...ica, en la que los macrófagos, los neutrófilos y las células dendríticas frenan el avance del virus y pueden incluso evitar que este provoque síntomas. A esta respuesta no específica le sigue una respuesta adaptativa en la que el organismo genera anticuerpos que se unen específicamente al virus. Estos anticuerpos son las proteínas denominadas inmunoglobulinas. El organismo también genera linfocitos T que reconocen y eliminan las células infectadas por el virus: es lo que se conoce como inmunidad celular. Esta respuesta adaptativa combinada puede eliminar el virus del organismo y, si la respuesta es suficientemente intensa, puede evitar el agravamiento de la enfermedad o la reinfección por el mismo virus. Este proceso se mide a menudo a través de la presencia de anticuerpos en la sangre.
more
Document d’information scientifique
24 avril 2020
Le développement d’une immunité face à un agent pathogène à la suite d’une infection naturelle comporte plusieurs étapes et prend généralement une à deux semaines. Une infection virale entraîne immédiatement une réponse immunit...aire innée, non spécifique, au cours de laquelle les macrophages, les neutrophiles et les cellules dendritiques ralentissent la progression du virus et peuvent même éviter l’apparition de symptômes. Cette réponse non spécifique est suivie d’une réponse adaptative, au cours de laquelle l’organisme produit des anticorps qui se lient spécifiquement au virus. Ces anticorps sont des protéines appelées immunoglobulines. L’organisme produit également des lymphocytes T qui reconnaissent et éliminent les cellules infectées par le virus. Cette réponse adaptative permet parfois d’éliminer le virus de l’organisme et, si elle est suffisamment forte, d’éviter l’aggravation de la maladie ou la réinfection par le même virus. Ce processus est souvent mesuré par la présence d’anticorps dans le sang.
more
While much progress has been achieved over the past year, the Region of the Americas has stubbornly remained the epicenter of the COVID-19 pandemic. PAHO is launching its 2021 COVID-19 Response Strategy and Donor Appeal to continue supporting Latin American and Caribbean countries and territories i...n their fight against COVID-19. This document outlines PAHO’s regional strategy for the year 2021 to sustain and scale-up the response to COVID‑19 pandemic in the Americas, suppress the community transmission of the virus and mitigate the longer-term health impact of the pandemic.
US$ 239 million is needed to support critical response efforts in the Americas between 1 January and 31 December 2021
more